rapidli
grow
understand
human
genet
pathway
includ
mediat
cancer
biolog
drug
respons
lead
increas
need
extens
reliabl
mutat
screen
popul
singl
patient
basi
describ
srtmelt
novel
technolog
enabl
highli
expand
enzymat
mutat
scan
human
sampl
germlin
lowlevel
somat
mutat
snp
discoveri
gcclampcontain
pcr
product
interrog
wildtyp
sampl
hybrid
gener
mismatch
posit
mutat
one
multipl
sequenc
inparallel
mismatch
convert
doublestrand
break
use
dna
endonucleas
surveyor
tm
oligonucleotid
tail
enzymat
attach
posit
mutat
novel
applic
pcr
enabl
select
amplif
mutationcontain
dna
fragment
subsequ
melt
curv
analysi
convent
nanotechnolog
realtim
pcr
platform
detect
sampl
contain
mutat
highthroughput
closedtub
manner
appli
srtmelt
screen
egfr
mutat
cell
line
clinic
sampl
demonstr
advantag
rapid
multiplex
mutat
scan
cancer
genet
variat
screen
biolog
medicin
screen
genet
chang
unveil
molecular
attribut
human
specimen
import
varieti
medic
applic
includ
genotyp
inherit
disord
predict
patholog
behavior
malign
identif
cancer
biomark
affect
treatment
decis
individu
patient
exampl
mutat
gene
like
egfr
profoundli
influenc
chemotherapeut
respons
lung
cancer
respons
modul
mutat
gene
signal
pathway
eg
kra
therefor
need
effici
highthroughput
mutat
screen
multipl
gene
along
identifi
signal
transduct
pathway
tumor
sampl
larg
portion
cancercaus
genet
chang
remain
unknown
occur
numer
posit
along
tumor
suppressor
gene
eg
atm
pten
mutat
scan
rather
detect
specif
mutat
frequent
requir
molecular
cancer
profil
sequenc
often
consid
gold
standard
comprehens
mutat
analysi
multicapillari
electrophoresi
resequenc
array
pyrosequenc
provid
platform
highli
parallel
genet
analysi
howev
expens
associ
techniqu
current
high
instrument
runningcost
sinc
somat
mutat
gene
rel
rare
event
ineffici
scan
mutat
use
expens
approach
sever
case
provid
unnecessari
data
anoth
issu
direct
sequenc
resequenc
array
difficulti
correspond
address
tel
fax
email
mmakrigiorgo
partnersorg
author
open
access
articl
distribut
term
creativ
common
attribut
noncommerci
licens
http
creativecommonsorglicens
permit
unrestrict
noncommerci
use
distribut
reproduct
medium
provid
origin
work
properli
cite
detect
small
fraction
mutat
allel
presenc
high
excess
normal
allel
frequent
case
clinic
cancer
sampl
less
expens
altern
rapid
prescreen
method
sscp
dgge
dhplc
ccm
cdce
hrmelt
wide
util
identifi
dna
fragment
contain
mutat
prior
perform
full
sequenc
enzymat
mutat
detect
base
mismatch
scan
enzym
like
muti
tdg
endonucleas
vii
mutat
prescreen
also
employ
albeit
modest
success
sinc
enzym
detect
possibl
mutat
delet
substanti
activ
homoduplex
dna
recent
enzymat
mutat
scan
method
base
surveyor
tm
celiii
nucleas
combin
dhplc
gel
electrophoresi
detect
introduc
show
satisfactori
select
reliabl
mutant
wildtyp
allel
detect
also
identifi
base
substitut
small
delet
import
cancer
biotechnolog
plant
genet
applic
till
method
reliabl
use
dhplc
examin
surveyor
tm
gener
dna
fragment
slow
endpoint
detect
method
restrict
examin
singl
dna
fragment
time
result
dna
fragment
sequenc
limit
analysi
cancer
specimen
numer
sampl
genet
region
need
screen
introduc
new
approach
enabl
surveyor
tm
scan
mutat
one
sever
pcr
product
simultan
select
amplifi
isol
mutationcontain
dna
fragment
via
linkermedi
pcr
select
amplifi
mutationcontain
dna
wildtyp
fragment
present
approach
decoupl
enzymat
mutat
scan
endpoint
detect
step
result
follow
enzymat
action
mismatch
chosen
dna
detect
method
realtim
pcr
gelcapillari
electrophoresi
microarraybas
detect
potenti
use
identifi
mutat
dna
fragment
simplex
multiplex
fashion
util
realtim
pcr
coupl
melt
curv
analysi
surveyor
tmmediat
real
time
melt
srtmelt
valid
new
technolog
demonstr
approach
increas
mutat
scan
throughput
order
magnitud
sever
sampl
prescan
mutat
enabl
mutat
scan
sever
pcr
fragment
simultan
mutationposit
sampl
directli
sequenc
somat
mutat
lowlevel
mutanttowildtyp
ratio
surgic
cancer
specimen
genom
dna
cell
line
defin
mutat
exon
exon
exon
exon
exon
extract
cell
line
purchas
american
type
cultur
collect
atcc
purchas
purifi
dna
avail
surgic
colon
lung
cancer
tumor
sampl
obtain
massachusett
gener
hospit
tumor
bank
follow
intern
review
board
approv
dna
egfr
mutationposit
cell
line
formalinfixedparaffinembed
lung
cancer
sampl
obtain
low
center
thorac
oncolog
dana
farber
cancer
institut
follow
intern
review
board
approv
isol
genom
dna
use
dneasi
tm
tissu
kit
qiagen
pcr
primer
contain
gcclamp
sequenc
gcclamp
portion
primer
well
genespecif
portion
primer
use
investig
list
supplementari
tabl
gcclamp
sequenc
ad
end
forward
revers
genespecif
primer
respect
vice
versa
twenti
microlit
pcr
reaction
perform
genom
dna
final
concentr
reagent
follow
jumpstart
tm
buffer
sigma
mm
dntp
mm
forward
revers
primer
jumpstart
tm
taq
polymeras
sigma
pcr
cycl
done
perkin
elmer
pcr
machin
cycl
condit
min
cycl
anneal
temperatur
decreas
touchdown
pcr
min
cycl
min
pcr
program
link
program
denatur
reanneal
pcr
product
min
fivemicrolit
pcr
product
ng
mix
ml
enhanc
tm
ml
surveyor
tm
transgenom
incub
min
follow
ad
ml
stopsolut
per
manufactur
protocol
inactiv
surveyor
tm
digest
product
purifi
pcr
qiaquick
tm
purif
kit
qiagen
elut
ml
water
experi
pcr
product
mix
approxim
equal
amount
pcr
product
wildtyp
dna
prior
form
crosshybrid
sequenc
facilit
detect
homozyg
mutat
addit
polyatail
end
follow
purif
surveyor
tm
treat
sampl
polyadenin
tail
ad
end
dna
fragment
reaction
ad
ml
purifi
surveyordigest
pcr
product
final
volum
ml
final
concentr
reaction
cocl
mm
datp
u
termin
transferas
new
england
biolab
reaction
incub
min
inactiv
heat
min
realtim
pcr
amplif
perform
use
titaniumtaq
tm
polymeras
bdbioscienc
clontech
smart
cycler
cepheid
realtim
pcr
machin
reaction
ad
ml
polyatail
dna
final
volum
ml
final
concentr
titanium
buffer
mm
dntp
lcgreen
idaho
technolog
mm
primer
mm
oligodtanchor
mix
gaccacgcgtatcgatgtcg
acttttttttttttttttv
v
repres
c
g
oligodtanchor
concentr
mm
per
race
protocol
titanium
tm
polymeras
clontechbd
bioscienc
thermocycl
program
follow
cycl
min
cycl
read
fluoresc
temperatur
titrat
perform
use
differ
denatur
temperatur
experiment
determin
condit
select
enabl
mutationcontain
fragment
amplifi
realtim
pcr
step
immedi
follow
realtim
differenti
melt
curv
analysi
use
smartcycl
tm
machin
dna
melt
perform
immedi
follow
pcr
smart
cycler
machin
sampl
heat
differenti
fluoresc
intens
curv
smooth
use
identif
melt
peak
alten
realtim
pcr
product
examin
via
dhplc
chromatographi
wave
tm
system
transgenom
mutationposit
pcr
product
purifi
via
pcr
purif
kit
qiagen
sequenc
use
primer
experi
repeat
least
three
time
independ
run
genom
dna
openarray
tm
highthroughput
massiv
parallel
realtim
pcr
platform
biotrov
test
compat
srtmelt
fortyeight
sampl
exon
pcr
product
gener
differ
lung
adenocarcinoma
sampl
mutationcontain
cell
line
process
via
hybrid
enzymat
step
srtmelt
realtim
pcr
openarray
tm
platform
perform
lightcycl
faststart
tm
dna
master
sybr
green
tm
roch
use
mm
mm
oligodtanchormix
primer
preposit
array
throughhol
polyatail
dna
templat
cycl
condit
follow
cycl
min
cycl
read
fluoresc
use
high
sensit
imag
camera
realtim
pcr
step
immedi
follow
realtim
differenti
melt
curv
analysi
raw
data
export
excel
softwar
analysi
openarray
tm
experi
repeat
twice
compani
headquart
estim
min
pcr
denatur
temperatur
pcr
effici
assum
initi
approxim
hypochrom
must
present
pcr
work
ie
given
sequenc
must
complet
denatur
otherwis
reform
immedi
temperatur
lower
reaction
inhibit
primer
bind
percent
melt
hypochrom
versustemperatur
relat
gcclampcontain
pcr
product
surveyor
tm
activitygener
product
estim
use
poland
algorithm
thermodynam
paramet
determin
blake
delcourt
mm
nacl
solut
use
order
forc
agreement
singl
point
predict
observ
valu
exon
sequenc
contain
short
gcclamp
normal
shift
account
influenc
min
nacl
mg
content
reaction
presenc
sybrgreenlcgreen
dye
proprietari
composit
pcr
buffer
min
pcr
product
estim
use
semiempir
determin
paramet
enrich
pcr
method
behn
et
al
use
sequenc
codon
mutat
exon
sampl
wildtyp
sampl
addit
second
method
amplif
via
primerlig
mutat
use
distinguish
mutant
wildtyp
sampl
virtu
de
novo
nlaiii
site
gener
mutant
sampl
codon
mutat
srtmelt
assay
convert
pcr
fragment
gener
posit
mutat
surveyor
tm
enzym
fulli
amplifi
sequenc
enabl
select
pcr
amplif
subsequ
quantit
pcr
detect
method
follow
denatur
reanneal
pcr
product
lead
format
crosshybrid
sequenc
posit
mutat
figur
sampl
expos
surveyor
tm
endonucleas
recogn
base
pair
mismatch
small
loop
high
specif
gener
break
dna
strand
mismatch
result
dna
fragment
particip
termin
transferas
tdt
reaction
lead
polynucleotid
tail
sequenti
addit
adenin
polyatail
end
realtim
pcr
reaction
subsequ
perform
use
adjust
condit
enabl
select
amplif
mutantonli
fragment
follow
realtim
melt
curv
analysi
identif
mutat
presenc
sybrgreen
tm
lcgreen
tm
dna
dye
enabl
select
amplif
mutationcontain
fragment
realtim
pcr
step
modifi
primer
employ
origin
amplif
genom
dna
figur
forward
primer
contain
region
specif
target
gene
high
melt
domain
gcclamp
revers
primer
contain
region
specif
target
gene
tail
vice
versa
follow
tdt
tail
reaction
primer
use
realtim
pcr
conjunct
primer
bind
polya
tail
denatur
temperatur
realtim
pcr
reaction
lower
enabl
pcr
amplif
fragment
contain
gcclamp
pcr
product
escap
digest
surveyor
tm
contain
gcclamp
figur
fragment
amplifi
effici
pcr
therebi
enabl
select
amplif
surveyor
tm
select
fragment
ie
effect
purif
mutationcontain
fragment
subsequ
closedtub
melt
curv
analysi
enabl
clear
separ
true
mutant
sequenc
pcr
dimer
artifact
srtmelt
requir
sizesepar
identif
enzymat
gener
fragment
one
sequenc
scan
parallel
unknown
mutat
singletub
reaction
surveyor
tm
simpl
procedur
enabl
specif
surveyor
tm
enzym
combin
throughput
conveni
realtim
pcr
rapid
mutat
scan
final
amplifi
mutat
sequenc
contain
defin
primer
end
direct
sequenc
enzymat
select
pcr
product
readili
possibl
follow
realtim
melt
step
enabl
sequenc
lowlevel
mutat
identifi
surveyor
tm
provid
initi
proof
principl
unknown
mutat
scan
use
srtmelt
util
cell
line
tumor
sampl
contain
sequencingidentifi
mutat
sever
posit
exon
figur
depict
dhplc
chromatogram
product
obtain
use
sampl
contain
exon
mutat
wildtyp
sampl
standard
surveyor
tm
dhplc
approach
first
employ
identifi
mutat
follow
pcr
amplif
exon
genom
dna
result
dhplc
trace
contain
singl
product
wildtyp
two
product
mutationcontain
sequenc
figur
curv
respect
next
srtmelt
use
screen
exon
sequenc
follow
pcr
amplif
simplex
multiplex
pcr
amplif
one
exon
pcr
product
g
c
c
l
p
selfhybrid
crosshybrid
wild
type
dna
gener
mismatch
posit
mutat
one
pcr
fragment
scan
mismatch
fragment
simultan
use
cel
surveyor
tm
enzym
cel
surveyor
tm
enzym
use
tdt
enzym
add
oligonucleotid
tail
eg
oligoda
end
serv
primer
anchor
undigest
fragment
digest
fragment
tdt
tail
dna
end
amplifi
mutat
fragment
coupl
w
real
time
melt
analysi
see
b
detect
mutat
via
close
tube
highthroughput
melt
curv
analysi
posit
sequenc
amplifi
mutat
dna
fragment
primer
crosshybrid
pcr
product
expos
surveyor
tm
tdt
tail
subsequ
realtim
pcr
run
differ
denatur
temperatur
product
examin
either
via
dhplc
via
realtim
meltingcurv
analysi
standard
denatur
temperatur
mutationcontain
sampl
contain
two
peak
correspond
anticip
amplif
surveyor
tm
digest
undigest
fragment
figur
curv
howev
pcr
denatur
temperatur
lower
eg
singl
pcr
product
gener
mutant
sampl
wildtyp
sampl
demonstr
product
figur
curv
figur
realtim
differenti
melt
curv
pcr
reaction
run
depict
peak
correspond
pcr
product
mutant
sampl
clearli
evid
absent
wildtyp
sampl
final
figur
depict
sequenc
srtmeltgener
pcr
fragment
well
direct
sequenc
genom
dna
mutat
evid
sampl
srtmelt
product
anticip
addit
polya
tail
posit
next
mutat
illustr
examin
select
srtmelt
dilut
mutant
wildtyp
dna
perform
use
dna
cell
harbor
exon
homozyg
mutat
realtim
pcr
reaction
perform
mutantto
wildtyp
ratio
distinguish
wildtyp
use
either
dhplc
figur
melt
curv
analysi
figur
sampl
direct
dideoxysequenc
could
identifi
mutat
ratio
mutanttowildtyp
data
shown
hand
sequenc
srtmelt
product
possibl
includ
lower
dilut
figur
srtmelt
sequenc
gener
trace
polya
tail
depict
presenc
posit
mutat
although
exact
nucleotid
chang
less
clear
one
exon
ie
posit
base
mutat
might
also
confus
mutat
reason
base
ambigu
exact
posit
mutat
probabl
understood
pcr
perform
follow
polya
tail
addit
contain
equimolar
mixtur
three
revers
primer
end
v
g
c
depend
exact
nucleotid
mutat
correct
primer
theori
prefer
two
primer
allow
effici
polymeras
extens
due
mismatch
end
howev
practic
allelespecif
pcr
step
occasion
allow
mismatch
primer
extens
enabl
one
version
primer
amplifi
posit
mutat
altern
incorpor
polya
tail
may
occur
base
exact
posit
mutat
conclud
certain
case
srtmelt
indic
posit
mutat
within
base
other
eg
exon
indic
posit
actual
nucleotid
chang
next
exon
amplifi
use
dna
group
surgic
lung
adenocarcinoma
sampl
srtmelt
use
screen
unknown
mutat
via
melt
curv
analysi
mutat
differ
posit
along
exon
present
sever
clinic
sampl
indic
shift
melt
profil
obtain
figur
subsequ
verifi
via
sequenc
set
sampl
srtmeltsequenc
detect
lowlevel
mutat
colon
cancer
specimen
direct
sequenc
fail
identifi
figur
figur
sequenc
sampl
indic
posit
polya
tail
addit
within
one
base
actual
nucleotid
chang
difficult
identifi
exclud
possibl
fals
posit
two
independ
rflpbase
method
use
verifi
presenc
mutat
thu
sinc
posit
polya
tail
addit
known
figur
codon
exon
mismatch
primer
approach
behn
et
al
use
introduc
mlui
restrict
site
wildtyp
sampl
codon
mutant
subsequ
restrict
mlui
enzym
follow
pcr
gener
product
mutat
sampl
wildtyp
sampl
supplementari
figur
frame
addit
verif
lowlevel
mutat
observ
mutat
gener
denovo
nlaiii
site
posit
mutat
accordingli
appli
amplif
via
primerlig
mutat
method
describ
previous
ligat
primer
nlaiiidigest
site
preferenti
amplifi
mutant
fragment
second
pcr
sequenc
pcr
product
identifi
mutat
supplementari
figur
frame
b
conclus
srtmelt
identifi
correctli
codon
lowlevel
mutat
miss
regular
sequenc
signific
exon
mutat
codon
associ
bad
prognosi
cancer
tabl
supplementari
data
depict
good
agreement
standard
surveyor
screen
srtmelt
screen
dideoxysequenc
except
lowlevel
mutat
discov
sampl
via
srtmelt
srtmeltsequenc
trace
two
sampl
exon
mutat
also
depict
data
figur
h
indic
lack
substanti
pcr
amplif
denatur
temperatur
fragment
contain
gcclamp
select
amplif
mutationcontain
fragment
sever
differ
mutat
posit
exon
estim
influenc
gcclamp
length
pcr
effici
versu
temperatur
pcr
amplif
fragment
gener
mutat
lie
differ
posit
along
sequenc
calcul
base
poland
algorithm
perform
predict
minimum
temperatur
substanti
pcr
amplif
plot
versu
experiment
observ
valu
three
possibl
simul
gcclamp
nucleotid
nt
gcclamp
gcclamp
dna
fragment
correspond
mutat
sever
posit
along
exon
also
simul
compar
experiment
observ
minimum
temperatur
gener
pcr
product
three
sampl
contain
mutat
differ
posit
along
exon
result
figur
indic
agreement
within
theoret
predict
experiment
observ
denatur
temperatur
region
combin
gcclamp
avail
mutat
exon
predict
result
select
amplif
mutationcontain
fragment
inhibit
gcclampcontain
fragment
predict
consist
experiment
result
obtain
pcr
temperaturetitr
experi
figur
develop
calcul
algorithm
thu
use
predict
appropri
pcr
denatur
temperatur
addit
pcr
fragmentgcclamp
combin
valid
srtmelt
util
method
identifi
mutat
addit
exon
figur
depict
chromatograph
obtain
mixtur
dna
cell
homozyg
mutat
exon
wildtyp
cell
screen
realtim
pcr
reaction
perform
differ
denatur
temperatur
product
examin
via
dhplc
via
melt
curv
analysi
comparison
also
observ
exon
denatur
temperatur
surveyor
tm
digest
undigest
pcr
product
amplifi
realtim
pcr
figur
curv
mutant
wildtyp
respect
lower
denatur
temperatur
singl
pcr
product
obtain
mutant
product
primer
dimer
obtain
wildtyp
sampl
figur
curv
figur
depict
melt
curv
obtain
follow
realtim
pcr
denatur
temperatur
mutant
wildtyp
sampl
srtmelt
subsequ
appli
manner
screen
mutat
exon
cell
line
surgic
colon
sampl
harbor
sequencingidentifi
mutat
includ
singlebas
frameshift
mutat
exon
list
supplementari
tabl
melt
curv
mutant
wildtyp
sampl
exon
depict
figur
e
data
indic
result
similar
obtain
exon
also
obtain
exon
detect
mutat
egfr
exon
particular
clinic
interest
alter
modul
respons
egfr
inhibitor
lung
adenocarcinoma
patient
figur
g
h
depict
applic
srtmelt
screen
dna
lung
cancer
cell
line
harbor
dhplcidentifi
alter
egfr
exon
includ
twocodon
delet
del
exon
abil
srtmelt
detect
lowlevel
egfr
mutat
evalu
perform
dna
dilut
heterozyg
egfr
exon
homozyg
sampl
mutanttowildtyp
ratio
detect
dilut
experi
figur
final
applic
srtmelt
detect
mutat
dna
formalinfix
paraffinembed
ffpe
sampl
examin
screen
four
clinic
ffpe
lung
adenocarcinoma
specimen
two
sampl
known
harbor
egfr
exon
mutat
two
neg
mutat
independ
evalu
via
dhplc
figur
demonstr
identif
mutat
statu
sampl
via
spcrmelt
multiplex
srtmelt
openarray
tm
base
srtmelt
increas
throughput
mutat
scan
signific
potenti
advantag
enzymat
mutat
scan
abil
screen
sever
sequenc
simultan
mutat
demonstr
srtmelt
use
parallel
scan
mutat
sever
pcr
product
mix
equimolar
amount
pcr
product
exon
contain
mutat
either
exon
exon
form
crosshybrid
sequenc
screen
mixtur
mutat
exon
singl
tube
use
srtmelt
depict
figur
follow
realtim
pcr
melt
curv
analysi
exon
exon
mutant
clearli
distinguish
wildtyp
sampl
figur
curv
next
mutant
exon
dna
sampl
first
dilut
wildtyp
exon
equimolar
mixtur
exon
prepar
screen
singl
tube
via
srtmelt
exon
mutat
distinguish
wildtyp
mixtur
exon
figur
curv
sinc
mutat
human
tumor
encount
exon
multiplex
singletub
srtmelt
reaction
could
use
identifi
mutat
encount
clinic
tumor
sampl
combin
multiplex
pcr
directli
genom
dna
approach
could
result
conveni
highthroughput
method
mutat
scan
adopt
realtim
pcr
platform
endpoint
detect
srtmelt
throughput
mutat
scan
increas
drastic
mutat
prescreen
approach
util
dhplc
capillari
gel
electrophoresi
demonstr
better
point
highli
parallel
nanotechnolog
platform
adopt
realtim
pcr
step
srtmelt
enabl
array
nl
volum
realtim
pcr
reaction
openarray
tm
system
carriedout
simultan
follow
differenti
melt
curv
analysi
proof
principl
compat
srtmelt
openarray
tm
exon
pcr
product
gener
differ
lung
adenocarcinoma
sampl
mutationcontain
cell
line
process
via
hybrid
enzymat
step
srtmelt
sampl
dispens
replic
nanolit
volum
reaction
openarray
tm
plate
prefabr
contain
appropri
primer
amplifi
realtim
pcr
reaction
use
denatur
temperatur
presenc
sybrgreen
dye
melt
curv
subsequ
obtain
use
openarray
tm
melt
curv
analysi
mode
pcr
growth
curv
smooth
differenti
melt
curv
obtain
distinguish
clearli
mutationcontain
sampl
wildtyp
sampl
figur
repres
result
reaction
furthermor
identif
mutationcontain
sampl
good
agreement
convent
nanotechnolog
platform
figur
versu
figur
data
indic
srtmelt
compat
highthroughput
nanotechnolog
detect
format
reiter
advantag
decoupl
enzymat
select
detect
step
comparison
throughput
use
convent
prescreen
method
dhplc
dhplcsurveyor
tm
srtmelt
tabl
indic
srtmelt
order
magnitud
faster
larg
number
sampl
screen
mutat
multiplex
srtmelt
format
adopt
throughput
increas
intrins
potenti
enzymat
mutat
scan
parallel
identif
mutat
principl
high
sinc
enzym
oper
numer
distinct
mismatchcontain
sequenc
moleculetomolecul
basi
thu
provid
highli
parallel
mutat
scan
howev
past
select
enzym
use
endpoint
detect
method
limit
realiz
potenti
enabl
surveyor
tm
endonucleas
recogn
select
mismatch
form
mutat
small
delet
follow
crosshybrid
sequenc
format
gener
mutationspecif
dna
fragment
amplifi
screen
via
differenti
melt
curv
analysi
replac
sizesepar
method
capillarygel
electrophoresi
dhplc
realtim
pcr
technolog
endpoint
detect
platform
abil
scan
one
sequenc
parallel
result
highli
increas
throughput
srtmelt
retain
abil
detect
divers
mutat
lowlevel
cel
iii
endonucleas
also
known
exonucleas
activ
dnaend
reason
srtmelt
design
attach
oligonucleotid
linker
dna
end
via
termin
transferas
tdt
instead
use
dna
end
exonucleas
activ
also
tend
degrad
attach
gcclamp
srtmelt
therebi
elimin
influenc
reduc
amplif
undigest
fragment
found
exposur
dna
crosshybrid
sequenc
surveyor
tm
limit
min
substanti
degrad
gcclamp
avoid
multiplex
mutat
detect
use
sever
pcr
product
simultan
size
gcclamp
pcr
amplicon
may
need
individu
adjust
ensur
mutat
along
sequenc
posit
pcr
product
includ
mixtur
screen
singl
realtim
pcr
temperatur
undigest
fragment
amplifi
calcul
tool
develop
work
use
guid
individu
design
gcclamp
srtmelt
detect
heterozyg
snp
well
mutat
mutat
prescreen
techniqu
presenc
snp
concurr
mutat
might
difficult
identifi
without
perform
sequenc
snp
occur
fix
posit
melt
peak
origin
snp
reproduc
pattern
melt
temperatur
thu
mani
case
distinguish
mutat
final
noteworthi
srtmelt
gener
methodolog
may
also
appli
isol
mutat
use
mismatchcut
enzym
surveyor
tm
enzym
satisfactori
properti
mutat
detect
becom
avail
detect
platform
realtim
pcrmelt
eg
dna
microarraybas
may
also
envis
follow
enzymat
mutat
select
summari
develop
new
method
rapid
mutat
scan
srtmelt
util
cel
iii
surveyor
tm
termin
deoxynucleotid
transferas
tdt
enzym
isol
amplifi
mutationcontain
dna
fragment
without
requir
dna
sizedepend
techniqu
besid
enabl
highli
increas
throughput
multiplex
mutat
screen
direct
sequenc
identifi
mutant
dna
fragment
srtmelt
also
retain
advantag
surveyor
endonucleas
altern
prescreen
method
reliabl
identif
genet
alter
present
low
fraction
sampl
srtmelt
provid
signific
advanc
unknown
mutat
scan
cancer
research
diagnost
well
gener
medic
biolog
biotechnolog
applic
